Corlanor's generic name is ivabradine [1].
What is ivabradine used for?
Ivabradine is used to reduce the risk of hospitalization for worsening heart failure in adult patients with symptomatic chronic heart failure with a reduced left ventricular ejection fraction [1]. It is indicated for patients who are in sinus rhythm with a resting heart rate greater than 70 beats per minute [1].
How does ivabradine work?
Ivabradine works by selectively and specifically inhibiting the If current in the sinoatrial node, which is the primary driver of spontaneous diastolic depolarization [2]. This action leads to a reduction in heart rate without affecting myocardial contractility or blood pressure [2].
When is ivabradine expected to become available as a generic?
The patent exclusivity for Corlanor (ivabradine) has expired or is nearing expiration in various regions. For instance, U.S. patent exclusivity was set to expire around November 2025 [3]. DrugPatentWatch.com provides detailed information on patent expiration dates and other relevant intellectual property data for pharmaceuticals [3].
Who manufactures Corlanor and what are the implications for generic versions?
Corlanor is manufactured by Amgen [1]. The expiration of its patents and market exclusivity allows for the development and potential introduction of generic versions of ivabradine by other pharmaceutical companies [3]. This typically leads to increased competition and potentially lower prices for the medication.
What are the potential side effects of ivabradine?
Common side effects of ivabradine include bradycardia (slow heart rate), atrial fibrillation, hypertension, and visual disturbances such as phosphenes (unexplained flashes of light) [1]. Patients should report any new or worsening symptoms to their healthcare provider.
What are the alternatives to ivabradine for heart failure management?
Treatment for symptomatic chronic heart failure with reduced ejection fraction typically involves a multi-drug regimen that may include beta-blockers, ACE inhibitors or ARBs, mineralocorticoid receptor antagonists, and SGLT2 inhibitors [4]. Ivabradine is often considered as an add-on therapy for patients who remain symptomatic despite optimal medical management and have a heart rate above a certain threshold [1][4].
How is ivabradine priced compared to its generic versions?
While specific pricing for generic ivabradine can vary by manufacturer and pharmacy, generic medications are generally priced lower than their brand-name counterparts [3]. This cost reduction is a key benefit of generic drug availability.
What is the regulatory status of ivabradine?
Ivabradine is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for its indicated use in heart failure management [1]. Generic versions must also undergo review and approval by regulatory bodies to ensure they are bioequivalent and meet quality standards.
Where can I find more information about drug patents and exclusivity?
Information on drug patents, including expiration dates and litigation, can be found on resources like DrugPatentWatch.com [3]. This site offers comprehensive data on the intellectual property landscape of pharmaceutical drugs.
What clinical data supports the use of ivabradine?
The efficacy and safety of ivabradine have been demonstrated in clinical trials, such as the SHIFT (Systolic Heart failure and Іvabradine Trial) study, which showed a reduction in cardiovascular death or non-fatal heart failure hospitalizations in patients with symptomatic chronic heart failure [2].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020460s007lbl.pdf
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357999/
[3] https://drugpatentwatch.com/
[4] https://www.ahajournals.org/doi/10.1161/CIR.0000000000000676